Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

被引:58
|
作者
Garg, Lohit [1 ]
Gupta, Manasvi [2 ]
Sabzwari, Syed Rafay Ali [1 ]
Agrawal, Sahil [3 ]
Agarwal, Manyoo [4 ]
Nazir, Talha [1 ]
Gordon, Jeffrey [1 ]
Bozorgnia, Babak [1 ]
Martinez, Matthew W. [1 ]
机构
[1] Lehigh Valley Hlth Network, Div Cardiol, 1200 S Cedar Crest Blvd, Allentown, PA 18103 USA
[2] Maulana Azad Med Coll, Delhi 110092, India
[3] Brown Univ, Div Cardiol, Providence, RI 02903 USA
[4] Univ Tennessee, Hlth Sci Ctr, Dept Internal Med, Memphis, TN 38163 USA
关键词
Atrial fibrillation; Hypertrophic cardiomyopathy; Treatment; Antiarrhythmic agents; CATHETER ABLATION; RHYTHM-CONTROL; TASK-FORCE; STROKE; RISK; OUTCOMES; AMIODARONE; DIAGNOSIS; GENETICS; EFFICACY;
D O I
10.1007/s10741-018-9752-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.
引用
收藏
页码:189 / 197
页数:9
相关论文
共 50 条
  • [31] Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?
    Frontera, Antonio
    Wilson, D. G.
    Sekhon, H.
    Duncan, E. R.
    Thomas, G.
    CLINICAL RESEARCH IN CARDIOLOGY, 2015, 104 (10) : 799 - 802
  • [32] Prediction of incident atrial fibrillation in hypertrophic cardiomyopathy
    Losi, Maria Angela
    Monda, Emanuele
    Lombardi, Raffaella
    Lioncino, Michele
    Canciello, Grazia
    Rubino, Marta
    Todde, Gaetano
    Caiazza, Martina
    Borrelli, Felice
    Fusco, Adelaide
    Cirillo, Annapaola
    Perillo, Errico Federico
    Sepe, Joseph
    Pacella, Daniela
    de Simone, Giovanni
    Calabro, Paolo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 395
  • [33] Outcomes of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
    Agarwal, Siddharth
    Munir, Muhammad Bilal
    Patel, Harsh
    Desimone, Christopher, V
    Deshmukh, Abhishek
    Asad, Zain Ul Abideen
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 207 : 1 - 3
  • [34] Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review
    Patricia Alphonse
    Sohaib Virk
    Jhonna Collins
    Timothy Campbell
    Stuart P. Thomas
    Christopher Semsarian
    Saurabh Kumar
    Clinical Research in Cardiology, 2021, 110 : 544 - 554
  • [35] Prognostic impact of newly detected atrial fibrillation in patients with hypertrophic cardiomyopathy following cardiac implantable electronic device implantation
    Hayashi, Hiroshi
    Iwasaki, Yu-Ki
    Arai, Toshiki
    Mimuro, Rei
    Hachisuka, Masato
    Maru, Yujin
    Fujimoto, Yuhi
    Oka, Eiichiro
    Hagiwara, Kanako
    Imori, Yoichi
    Yamamoto, Teppei
    Murata, Hiroshige
    Yodogawa, Kenji
    Takano, Hitoshi
    Shimizu, Wataru
    HEART AND VESSELS, 2021, 36 (05) : 667 - 674
  • [36] Atrial fibrillation management during septal myectomy for hypertrophic cardiomyopathy: A systematic review
    Seco, Michael
    Lau, Jonathan C. L.
    Medi, Caroline
    Bannon, Paul G.
    ASIAN CARDIOVASCULAR & THORACIC ANNALS, 2022, 30 (01) : 98 - 107
  • [37] Oral anticoagulation in patients with hypertrophic cardiomyopathy and non-valvular atrial fibrillation in Japan
    Kitaoka, Hiroaki
    Carroll, Robert
    Eugene, Natalie
    Teixeira, Bruno Casaes
    Matsuo, Yukako
    Kubo, Toru
    ESC HEART FAILURE, 2025, 12 (01): : 326 - 337
  • [38] QTc Interval Prolongation Predicts Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
    Wen, Song-Nan
    Liu, Nian
    Li, Song-Nan
    Wu, Xiao-Yan
    Salim, Mohamed
    Kang, Jun-Ping
    Ning, Man
    Wu, Jia-Hui
    Ruan, Yan-Fei
    Yu, Rong-Hui
    Long, De-Yong
    Tang, Ri-Bo
    Sang, Cai-Hua
    Jiang, Chen-Xi
    Bai, Rong
    Du, Xin
    Dong, Jian-Zeng
    Liu, Xiao-Hui
    Ma, Chang-Sheng
    CIRCULATION JOURNAL, 2015, 79 (05) : 1024 - 1030
  • [39] Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation
    Tsuda, Toyonobu
    Hayashi, Kenshi
    Fujino, Noboru
    Konno, Tetsuo
    Tada, Hayato
    Nomura, Akihiro
    Tanaka, Yoshihiro
    Sakata, Kenji
    Furusho, Hiroshi
    Takamura, Masayuki
    Kawashiri, Masa-aki
    Yamagishi, Masakazu
    HEART RHYTHM, 2019, 16 (06) : 829 - 837
  • [40] Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
    Rozen, Guy
    Elbaz-Greener, Gabby
    Marai, Ibrahim
    Andria, Nizar
    Hosseini, Seyed Mohammadreza
    Biton, Yitschak
    Heist, E. Kevin
    Ruskin, Jeremy N.
    Gavrilov, Yulia
    Carasso, Shemy
    Ghanim, Diab
    Amir, Offer
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (13):